Cyclin A2 (CCNA2) (CCNA2)

Cyclin A2 is a master regulatory protein, encoded by the CCNA2 gene, that plays a central role in controlling the progression of the eukaryotic cell cycle by binding and activating cyclin-dependent kinases CDK1 and CDK2 [2][10][19]. It is uniquely required for both the S phase, where the Cyclin A2-CDK2 complex initiates and maintains DNA replication, and the G2/M transition, where the Cyclin A2-CDK1 complex triggers entry into mitosis [8][12][14]. In oncological contexts, Cyclin A2 is frequently overexpressed in various malignancies, including breast, lung, and liver cancers, where it correlates with high proliferation rates, genomic instability, and poor patient prognosis [1][16][17]. Conversely, the silencing of Cyclin A2 in postnatal mammalian cardiomyocytes is a primary factor preventing adult heart regeneration; research into reactivating this gene via adenoviral delivery (Ad-hCCNA2) has demonstrated potential for repairing heart tissue and restoring function after myocardial infarction [4][7][11]. Current therapeutic development focuses on either inhibiting its kinase activity to halt tumor growth or employing gene therapy to reinitiate cell division for cardiac repair and neuroregeneration [3][9][15][21].

Other names

CCN1CCNACyclin-A2Cyclin-A

Inhibition of Cyclin A2-CDK kinase complex activity, transcriptional and post-translational downregulation of CCNA2 expression, and adenoviral vector-mediated gene delivery for protein overexpression.